Valor do Antígeno Carcinoembriônico no Acompanhamento das Neoplasias Malignas do Trato Gastrentérico

• Autor(a) principal: Fonseca, Léa Mirian Barbosa da
• Data de Publicação: 2023
• Outros Autores: Corbo, Rossana, Correa, Heloisa Helena, Silveira, Neusa Prado R. da
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista Brasileira de Cancerologia (Online)
• Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/3245
• topic: Antígeno Carcinoembriônico; Marcador Câncer; Radioimunoensaio; Cintilografia; Carcinoembrionic Antigen; Cancer Marker; Radioimmunoassay; Scintigraphy

The role of sequential determination of CEA levels in patients with malignant tumors of the G. I. tract was evaluated. Sixty one patients had their history reviewed: 22 beared rectal lesions (36,06%), 18 had large bowel lesions (29,54%), eight had gastric tumors (13,11%), five had sigmoid lesions (8,19%), four had anal canal lesions (6,55%) and four had cecum lesions (6,55%). High levels of CEA and the presence of tumor were associated in 63% of the patients, and in 60,6% of those with metastatic disease high levels of CEA were also found. Adenocarcinoma was the most common histologic type found and CEA levels were high in all well differentiated tumors. High levels of CEA correlated better with the presence of metastatic disease than did liver scintigraphy. This was made clear by the findings of abnormal levels of CEA and normal scintigraphy. Survival of patients with normal preoperative levels of CEA was 100%. Of those patients with abnormal preoperative CEA levels, only 40% were alive af ter 36 months. The possible interferences in serum dosages of CEA and its interpretation, the importance of measuring the tumor marker in tissues, and the need of establishing preoperative follow-up protocols for the better assesment of the CEA dosages and the better evaluation of malignant G. I. tract tumors are stressed.